Systemic inhibition of HIF-1α by 2ME2 significantly decreased osteolytic lesion area and reduced tumor burden in a prevention model of MDA-MB-231 breast cancer bone metastasis, consistent with the previous studies using 4T1 cells [42]. The gene discussed is HIF1A; the disease is neoplasm.